- Joined
- Nov 12, 2012
- Posts
- 27,638
- Qantas
- Platinum
- Virgin
- Platinum
- Star Alliance
- Silver
The Bivalent vaccine at best decreases infection by at best 40%. Within 100 days that has fallen to 20%. But in the initial Phase 3 trials if that had been the result they would not have been approved. The cut off point was 50%.
40% sounds an excellent number for me, about to go on a holiday for a month or two overseas. But I acknowledge the cost to the government of going through an approvals process of a vaccine that may have a limited target market.
. And what is happening around the world now? An increase in cardiac deaths particularly sudden death. It may be due to covid itself but then why didn'y this happen in the AZ and J&J trials.
Maybe a lag affect of people being locked up during the Covid years, and not seeking early intervention on various heart related and other issues (cheeky, I know, based on our conversation the other day).
"The most expensive price per dose paid by the government was for the recent purchase of bivalent booster doses from each manufacturer, including 105 million doses at $30.48 per dose from Pfizer and 66 million doses at $26.36 per dose from Moderna (or a weighted average price per dose of $28.89).
Again, in my case, I’m talking about bearing the retail cost of the vaccine and it’s being administered myself, but there are of course behind the scenes costs to the government of approval etc and I acknowledge that’s a hurdle if the vaccine has a limited target market. But say some vaccine is approved by the TGA for whatever reason then again. I’d hope there wouldn’t be substantial barriers to me getting it as a precautionary measure.